Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 16, Issue 5, 1998, Pages 533-540

  Ichikawa, Y ^a   Yamada, C ^a   Horiki, T ^a   Hoshina, Y ^a   Uchiyama, M ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

D dimer; Disease activity; Matrix metalloproteinase; Plasmin; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

D DIMER; FIBRINOLYTIC FACTOR; PLASMIN; STROMELYSIN;

ADULT; AGED; ARTICLE; DISEASE ACTIVITY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 0031656122     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. AREND WP, DAYER J-M: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-15.
2. BRENNAN FM, BROWNE KA, GREEN PA, JASPAR J-M, MAINI RN, FELDMANN M: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-α (cA2) therapy. Br J Rheumatol 1997; 36: 643-50.
3. OKADA Y, HARRIS ED JR, NAGASE H: The precursor of a metalloendopoptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J 1988; 254: 731-41.
4. OBATA K, IWATA K, OKADA Y et al.: A one-step sandwich enzyme immunosssay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clinica Chimica Acta 1992; 211: 59-72.
5. OKUDA Y, TAKEUCHI N, TOMITA K, NAKANISHI I, NAGASE H: Immunolocalisation of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): Correlation with rheumatoid arthritis. Ann Rheum Dis 1989; 48: 645-53.
6. KOMIYA Y: Immunohistochemical localization of tissue inhibitor of metalloproteinases (TIMP) and stromelysin in human joint synovium. Nippon Kansetu Geka Gakkaishi 1992; 11: 59-70 (in Japanese).
7. SASAKI S, IWATA H, ISHIGURO N, OBATA K, MIURA T: Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1994; 13: 228-33.
8. YOSHIHARA Y, OBATA K, FUJIMOTO N, YAMASHITA K, SHIMMEI M: Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinase-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 969-75.
9. ISHIGURO N, ITO T, OBATA K, FUJIMOTO N, IWATA H: Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996; 23: 1599-1604.
10. RONDAY HK, SMITS HH, VAN MUIJEN GNP et al.: Difference in expression of the plasminogen system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996; 35: 416-23.
11. SUZUKI K, ENGHILD JJ, MORODOMI T, SALVESEN G, NAGASE H: Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (Stromelysin). Biochemistry 1990; 29: 10261-70.
12. SASAKI S, ISHIGURO N, KAWASAKI S, SASAKI Y, IWATA H: Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Ryumachi-ka 1994; 12: 435-43 (in Japanese).
13. SHINGU M, OBATA K, EZAKI I et al.: Stromelysin-1 (MMP-3) level in the sera from patients with rheumatoid arthritis and other connective tissue diseases - clinical significance in early onset rheumatoid arthritis. Ryumachi 1995; 35: 15-24 (in Japanese).
14. BUSSO N, PÉCLAT V, SO A, SAPPINO A-P: Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997; 56: 550-7.
15. RONDAY HK, AMITS HH, QUAX PHA et al.: Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1987; 36: 9-15.
16. WEINBERG JB, PIPPEN AMM, GREENBERG CS: Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1991; 34: 996-1005.
17. GABAZZA EC, OSAMU T, YAMAKAMI T et al.: Correlation between clotting and collagen metabolism markers in rheumatoid arthritis. Thrombosis Haemostas 1994; 71: 199-202.
18. BECKHAM JC, CALDWELL DS, PETERSON BL et al.: Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992; 12: 353-61.
19. GOTOH H, YAMADA H, YOSHIHARA Y, KIKUCHIT, OBATA K, SHINMEI M: Levels of matrix metalloproteinase-3 and urokinase-type plasminogen activator in knee synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Ryumachi 1997; 37: 3-8 (in Japanese).
20. ICHIKAWA Y, HOSHINA Y, HORIKI T, YAMADA C, UCHIYAMA M, TAKAYA M: Molecular markers of coagulation and fibrinolysis as indicators for the disease activity of rheumatoid arthritis. Jpn J Rheumatol 1997; 7: 173-81.
21. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25; 1271-7.
23. STEINBROKER O, TRAEGER CH, BATTERMAN RC: Therapeutic criteria in rheumatoid arthritis. J Am Med Ass 1949; 140: 659-62.
24. LANSBURY J: Methods for evaluating rheumatoid arthritis. In HOLLANDER JL, MCCARTY DJ (Eds.): Arthritis and Allied Conditions, 7th ed., Philadelphia, Lea and Febiger 1966; 269-91.
25. GUZMAN J, CARDIEL MH, ARCE-SALLINAS A, SÁNCHEZ-GUERRERO J, ALARCÓN-SEGOVIA D: Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-8.
26. SEKI M, UZUKI M, OHMOTO H et al.: Matrix metalloproteinase 9 (MMP-9) in patients with rheumatoid arthritis. Jpn J Rheumatol 1997; 7: 197-209.
27. SHIN H, NAKAJIMA T, KITAJIMA I et al.: Thrombin receptor-mediated synovial proliferation in patients with rheumatoid arthritis. Clin Immunol Immunopathol 1995; 76: 225-33.
28. INOH M, TOKUDA M, KIKUCHI H, KURATA N, TAKAHARA J: Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis. Arthritis Rheum 1996; 39: 287-91.
29. MANICOURT D-H, FUJIMOTO N, OBATA K, THONAR EJ-MA: Serum levels of collagenase, stromelysin-1, and TIMP-1. Age-and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994; 37: 1774-83.